DCOY Stock Research Snapshot: Pipeline, Catalysts, and Cash Runway

Decoy Therapeutics Inc | Needs refresh | Last updated: 2026-06-01T17:55:29Z

TickerDCOY

Market Cap4.5M

Cash RunwayRunway 6-12 months

Next Catalystn/a

Public Research Snapshot

Decoy Therapeutics Inc is a publicly tracked healthcare company. This research snapshot summarizes public information on pipeline assets, clinical trials, upcoming catalysts, SEC filings, and cash runway estimates for intravitreal injection of RC28-E in Diabetic Macular Edema (Phase 2).

Pipeline

Asset	Indication	Modality	Stage	Public Note
NF-kappaB Decoy	Atopic Dermatitis	n/a	Phase 1 \| Phase 2	Public pipeline row
edifoligide (E2F Decoy)	Hyperplasia \| Chronic Renal Failure	n/a	Phase 1 \| Phase 2	Public pipeline row
AXER-204	Chronic Spinal Cord Injury	n/a	Phase 1 \| Phase 2	Public pipeline row
CGT003 (E2F Duplex Decoy)	n/a	n/a	Phase 2 \| Phase 3	Public pipeline row
intravitreal injection of RC28-E	Diabetic Macular Edema	n/a	Phase 2	Public pipeline row

Catalyst Preview

No public catalyst rows matched this view yet.

Cash Runway Preview

Estimated cash runway: Runway 6-12 months.

This is an automated estimate and may differ from company guidance.

Recent SEC Filings

No public filing rows are loaded yet.

Clinical Trial Activity

NCT ID	Phase	Status	Enrollment	Primary Completion
NCT00041925	Phase 2 \| Phase 3	COMPLETED	1400	2004-11
NCT00125333	Phase 1 \| Phase 2	COMPLETED	75	2005-11
NCT03989440	Phase 1 \| Phase 2	COMPLETED	52	2022-06-21
NCT04782115	Phase 2	COMPLETED	156	2023-07-31
NCT00086164	Phase 1 \| Phase 2	TERMINATED	n/a	n/a

Scientific Context

literature_publication | Therapeutic Efficacy of PB101 and Chemotherapy Combination in Preclinical Gastric Cancer Models.
literature_publication | Engineered cargo-free nanoparticle decoys for phagocytic modulation of macrophages.
literature_publication | The therapeutic effects of the VEGF decoy receptor fusion protein VEGF-Grab in chronic inflammatory diseases.
literature_publication | A randomized phase II trial of gemcitabine, nab-paclitaxel, cisplatin with or without a medically supervised ketogenic diet for patients with metastatic pancreatic cancer.
literature_publication | In vivo HSC gene therapy enables sustained eCD4-Ig expression for SIV prevention.

Want the full DCOY research brief?

Subscribe for source-linked catalyst analysis, cash runway monitoring, and clinical trial change alerts.

Get the weekly biotech catalyst watchlist

This page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell securities. Data may be incomplete or delayed. Cash runway and catalyst timing estimates are derived from public sources and may differ from company guidance.